menu

ReachMD

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Are you providing the best care for patients with HER2-positive gastrointestinal cancers?

Live Broadcast
1.50 available credits
Information
January 19, 2024
09:30 PM - 11:00 PM EST
Virtual
United States
ReachMD Healthcare Image
Details
Presenters
Comments

  • Overview

    Treatment for HER2-positive gastrointestinal malignancies is rapidly evolving. This engaging live program is designed to share practical know-how in the care of patients with gastric/gastroesophageal junction, colorectal, and biliary tract cancers. Topics to be discussed include best practices in HER2 evaluation, current and emerging treatment and sequencing strategies, and mitigation and management of adverse events. Join this expert-led program and begin the journey to optimize care for your patients with HER2-gastrointestinal cancers.

  • Agenda

    Times listed is PST

    6:30pm: Welcome and Introductions
    6:35pm-8:00pm Topics to Include

    • HER2 Heterogeneity: Clinical Implications
    • Unmet Needs in Second-Line HER2+ G/GEJ Cancers
    • Emerging Directions in HER2+ G/GEJ Cancers
    • HER2-Amplified Metastatic CRC: Progression Following Frontline Therapy
    • The Emerging Role of HER2 in Biliary Tract Cancers
    • Treatment-Related Toxicities With HER2-Directed Therapy in GI Cancers

    Not an official event of the 2024 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kristen K. Ciombor, MD, MSCI 
    Associate Professor of Medicine 
    Division of Hematology/Oncology  
    Vanderbilt University Medical Center 
    Nashville, TN   

    Dr. Ciombor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consultant/advisory board: Bayer, Exelixis, Incyte, Merck, Personalis, Pfizer, Replimune, Seagen,  
    Research grants: Array, BMS, Daiichi Sankyo, Genentech, Incyte, Merck, NuCana, Pfizer/Calithera, Seagen 

    Faculty:
    James J. Harding, MD
    Gastrointestinal Oncologist
    Early Drug Development Specialist
    Memorial Sloan Kettering Cancer Center
    New York, NY

    No relevant relationships have been reported at this time.

    Filippo Pietrantonio, MD
    Medical Oncologist
    IRCCS National Cancer Institute
    Milan, Italy

    No relevant relationships have been reported at this time.

    Kanwal P.S. Raghav, MD, MBBS
    Associate Professor, Department of Gastrointestinal Medical Oncology
    Medical Director, Division of Ambulatory Treatment Centers
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Dr. Raghav has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Abbvie, AstraZeneca, Bayer, Eisai, Daiichi Sankyo, Inc., Sanofi, Seagen     
    Research: Abbvie, AstraZeneca, Bayer, Guardant Health, HiberCell, Innovent, Janssen, Merck/Serono, Roche/Genentech, Seagen, Xencor 

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Sara R. Fagerlie, PhD, CHCP, has nothing to disclose.
    • Elizabeth Lurwick has nothing to disclose.
    • Andrea Mathis has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Integrate a multidisciplinary-based approach with pathologists to optimally implement biomarker testing in patients with gastrointestinal (GI) malignancies
    • Improve the identification of patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/gastroesophageal junction cancer
    • Contextualize the evidence from ongoing trials exploring HER2-directed therapy with the potential to impact guidelines and new indications
    • Evaluate the clinical significance of HER2 alterations and early clinical trial evidence in patients with biliary tract cancers
    • Incorporate therapeutic options to improve response and durability following progression on frontline therapy in HER2-amplified metastatic colorectal cancer
    • Develop multidisciplinary care pathways to improve the early recognition and management of treatment-related adverse events with HER2-directed therapies in patients with GI malignancies

  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, nurse navigators and nurse oncology team members, gastroenterologists, pharmacists, pathologists, and other healthcare professionals who treat patients with GI cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Presenters

Facebook Comments

Details
Presenters
Comments
Recommended

  • Overview

    Treatment for HER2-positive gastrointestinal malignancies is rapidly evolving. This engaging live program is designed to share practical know-how in the care of patients with gastric/gastroesophageal junction, colorectal, and biliary tract cancers. Topics to be discussed include best practices in HER2 evaluation, current and emerging treatment and sequencing strategies, and mitigation and management of adverse events. Join this expert-led program and begin the journey to optimize care for your patients with HER2-gastrointestinal cancers.

  • Agenda

    Times listed is PST

    6:30pm: Welcome and Introductions
    6:35pm-8:00pm Topics to Include

    • HER2 Heterogeneity: Clinical Implications
    • Unmet Needs in Second-Line HER2+ G/GEJ Cancers
    • Emerging Directions in HER2+ G/GEJ Cancers
    • HER2-Amplified Metastatic CRC: Progression Following Frontline Therapy
    • The Emerging Role of HER2 in Biliary Tract Cancers
    • Treatment-Related Toxicities With HER2-Directed Therapy in GI Cancers

    Not an official event of the 2024 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kristen K. Ciombor, MD, MSCI 
    Associate Professor of Medicine 
    Division of Hematology/Oncology  
    Vanderbilt University Medical Center 
    Nashville, TN   

    Dr. Ciombor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consultant/advisory board: Bayer, Exelixis, Incyte, Merck, Personalis, Pfizer, Replimune, Seagen,  
    Research grants: Array, BMS, Daiichi Sankyo, Genentech, Incyte, Merck, NuCana, Pfizer/Calithera, Seagen 

    Faculty:
    James J. Harding, MD
    Gastrointestinal Oncologist
    Early Drug Development Specialist
    Memorial Sloan Kettering Cancer Center
    New York, NY

    No relevant relationships have been reported at this time.

    Filippo Pietrantonio, MD
    Medical Oncologist
    IRCCS National Cancer Institute
    Milan, Italy

    No relevant relationships have been reported at this time.

    Kanwal P.S. Raghav, MD, MBBS
    Associate Professor, Department of Gastrointestinal Medical Oncology
    Medical Director, Division of Ambulatory Treatment Centers
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Dr. Raghav has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Abbvie, AstraZeneca, Bayer, Eisai, Daiichi Sankyo, Inc., Sanofi, Seagen     
    Research: Abbvie, AstraZeneca, Bayer, Guardant Health, HiberCell, Innovent, Janssen, Merck/Serono, Roche/Genentech, Seagen, Xencor 

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Sara R. Fagerlie, PhD, CHCP, has nothing to disclose.
    • Elizabeth Lurwick has nothing to disclose.
    • Andrea Mathis has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Integrate a multidisciplinary-based approach with pathologists to optimally implement biomarker testing in patients with gastrointestinal (GI) malignancies
    • Improve the identification of patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/gastroesophageal junction cancer
    • Contextualize the evidence from ongoing trials exploring HER2-directed therapy with the potential to impact guidelines and new indications
    • Evaluate the clinical significance of HER2 alterations and early clinical trial evidence in patients with biliary tract cancers
    • Incorporate therapeutic options to improve response and durability following progression on frontline therapy in HER2-amplified metastatic colorectal cancer
    • Develop multidisciplinary care pathways to improve the early recognition and management of treatment-related adverse events with HER2-directed therapies in patients with GI malignancies

  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, nurse navigators and nurse oncology team members, gastroenterologists, pharmacists, pathologists, and other healthcare professionals who treat patients with GI cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Presenters

Facebook Comments

Recommended

Schedule26 Jul 2024
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended